Teladoc Health Inc
For the period ended Sep 30, 2024. Filed Oct 31, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Oct 31, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Other Information
During the three months ended September 30, 2024, the following officer (as defined in Rule 16a-1(f) of the Securities Exchange Act of 1934) adopted a Rule 10b5-1 trading arrangement (as defined in Item 408 of Regulation S-K of the Securities Act of 1933), which was intended to satisfy the affirmative defense of Rule10b5-1(c):
On September 13, 2024, Michael Waters, our Chief Operating Officer, adopted a Rule 10b5-1 trading plan that provides for the sale of up to 105,703 shares of our common stock through December 2025.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.